Helus Pharma Inc. (HELP)

$7.73 -1.24 (-13.82%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 864,772
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterate...

Industry: Biotechnology
Sector: Healthcare
Phone: 908-764-8385
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
BelieveinthePK
BelieveinthePK Apr. 30 at 12:55 AM
$HELP what Mastacash said…
0 · Reply
Mastacash
Mastacash Apr. 29 at 11:35 PM
$HELP So the bears come on the board, call the company a shell company,,yet no insiders have sold any shares, and as you can see below, they admit hlp003 is going to be the best treatment..this just makes me want to buy more at a 200 mil market cap, while peers are in the billions.
0 · Reply
kev90123
kev90123 Apr. 29 at 11:02 PM
$HELP I've said numerous times I believe HLP003 will be the go to psilocybin related treatment in the future. Someone will make a lot of money on it, it just wont be Helus shareholders. Management's incompetence has gotten them to a point where they either dilute existing shareholders into oblivion or sell the program before commercialization for pennies on the dollar.
1 · Reply
Mastacash
Mastacash Apr. 29 at 10:06 PM
$HELP
0 · Reply
Mastacash
Mastacash Apr. 29 at 10:06 PM
$HELP
0 · Reply
kev90123
kev90123 Apr. 29 at 8:21 PM
$HELP @HelusPharmaIR Doug said we needed the stock price to be above $5 so institutions would be able to buy. We need a reverse split asap otherwise they won't be able to buy anymore! Hurry!
0 · Reply
Buckwacker
Buckwacker Apr. 29 at 7:59 PM
$HELP Well shit…. I don’t even know what to say, think, damn it man….
0 · Reply
kev90123
kev90123 Apr. 29 at 5:59 PM
$HELP
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 29 at 5:58 PM
$HELP Current Stock Price: $4.97 Contracts to trade: $5.0 HELP May 15 2026 Call Entry: $0.40 Exit: $0.68 ROI: 69% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
kev90123
kev90123 Apr. 29 at 1:47 PM
$HELP All you needed to do is look at the founders of @HelusPharmaIR to realize this is a shell company. Paul Glavine didnt graduate from college and lives in the Bahamas and Eric So should arguably be in jail for crypto fraud.
1 · Reply
Latest News on HELP
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Apr 28, 2026, 7:30 AM EDT - 1 day ago

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Apr 23, 2026, 7:30 AM EDT - 6 days ago

Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

How Trump's psychedelics executive order could unlock stalled cannabis reform

Apr 20, 2026, 2:05 PM EDT - 9 days ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX GHRS

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Apr 20, 2026, 8:15 AM EDT - 9 days ago

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Apr 20, 2026, 8:00 AM EDT - 9 days ago

Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

Apr 20, 2026, 6:43 AM EDT - 9 days ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB GHRS

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Apr 16, 2026, 7:30 AM EDT - 13 days ago

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Mar 12, 2026, 7:30 AM EDT - 6 weeks ago

Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Mar 5, 2026, 10:38 AM EST - 7 weeks ago

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Cybin Transcript: Study result

Mar 5, 2026, 7:30 AM EST - 7 weeks ago

Cybin Transcript: Study result

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Feb 24, 2026, 7:45 AM EST - 2 months ago

Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

Feb 17, 2026, 7:30 AM EST - 2 months ago

Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Feb 13, 2026, 7:31 AM EST - 2 months ago

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Dec 30, 2025, 3:33 PM EST - 4 months ago

Cybin Initiates At-The-Market Equity Program of up to US$100 Million

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Dec 18, 2025, 12:29 PM EST - 4 months ago

Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Cybin Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 7:30 AM EST - 5 months ago

Cybin Transcript: Jefferies London Healthcare Conference 2025

Cybin Earnings Call Transcript: Q2 2026

Nov 13, 2025, 8:00 AM EST - 5 months ago

Cybin Earnings Call Transcript: Q2 2026

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 5 months ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 6 months ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:30 PM EST - 6 months ago

Cybin Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 6 months ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin Transcript: Future of Health Summit 2025

Nov 5, 2025, 2:00 PM EST - 6 months ago

Cybin Transcript: Future of Health Summit 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 6 months ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 6 months ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 6 months ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 6 months ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 7 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 17, 2025, 9:20 AM EDT - 8 months ago

Cybin Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 8 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 11:00 AM EDT - 8 months ago

Cybin Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 8 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin Transcript: Cantor Global Healthcare Conference 2025

Sep 5, 2025, 10:20 AM EDT - 8 months ago

Cybin Transcript: Cantor Global Healthcare Conference 2025

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 8 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 8 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 8 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 9 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Transcript: AGM 2025

Aug 18, 2025, 10:00 AM EDT - 9 months ago

Cybin Transcript: AGM 2025

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 9 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 2:30 PM EDT - 9 months ago

Cybin Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 9 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 9 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 10 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 10 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 10 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 10 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 11 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 11 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 11 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin Transcript: Fireside Chat

May 29, 2025, 11:00 AM EDT - 11 months ago

Cybin Transcript: Fireside Chat

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 1 year ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 1 year ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 1 year ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 13, 2025, 11:30 AM EST - 1 year ago

Cybin Transcript: Lytham Partners 2025 Investor Healthcare Summit

Cybin Transcript: Study Update

Dec 11, 2024, 11:00 AM EST - 1 year ago

Cybin Transcript: Study Update

Cybin Transcript: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cybin Transcript: Status Update

Cybin Transcript: Water Tower Research Fireside Chat

Oct 8, 2024, 3:00 PM EDT - 1 year ago

Cybin Transcript: Water Tower Research Fireside Chat

Cybin Transcript: TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024

Sep 26, 2024, 10:00 AM EDT - 1 year ago

Cybin Transcript: TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit 2024

Cybin Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 8:30 AM EDT - 1 year ago

Cybin Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Cybin Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 2:00 PM EDT - 1 year ago

Cybin Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Cybin Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Cybin Transcript: H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Cybin Transcript: A.G.P./Alliance Global Partners Healthcare Company Showcase

May 21, 2024, 12:40 PM EDT - 2 years ago

Cybin Transcript: A.G.P./Alliance Global Partners Healthcare Company Showcase

Cybin Transcript: Status Update

Mar 13, 2024, 8:30 AM EDT - 2 years ago

Cybin Transcript: Status Update

Cybin Transcript: Study Update

Nov 30, 2023, 10:00 AM EST - 2 years ago

Cybin Transcript: Study Update

Cybin Transcript: Study Result

Nov 1, 2023, 11:00 AM EDT - 2 years ago

Cybin Transcript: Study Result

Cybin Transcript: M&A Announcement

Aug 28, 2023, 11:30 AM EDT - 2 years ago

Cybin Transcript: M&A Announcement

Cybin Transcript: R&D Day 2023

Feb 28, 2023, 10:00 AM EST - 3 years ago

Cybin Transcript: R&D Day 2023

BelieveinthePK
BelieveinthePK Apr. 30 at 12:55 AM
$HELP what Mastacash said…
0 · Reply
Mastacash
Mastacash Apr. 29 at 11:35 PM
$HELP So the bears come on the board, call the company a shell company,,yet no insiders have sold any shares, and as you can see below, they admit hlp003 is going to be the best treatment..this just makes me want to buy more at a 200 mil market cap, while peers are in the billions.
0 · Reply
kev90123
kev90123 Apr. 29 at 11:02 PM
$HELP I've said numerous times I believe HLP003 will be the go to psilocybin related treatment in the future. Someone will make a lot of money on it, it just wont be Helus shareholders. Management's incompetence has gotten them to a point where they either dilute existing shareholders into oblivion or sell the program before commercialization for pennies on the dollar.
1 · Reply
Mastacash
Mastacash Apr. 29 at 10:06 PM
$HELP
0 · Reply
Mastacash
Mastacash Apr. 29 at 10:06 PM
$HELP
0 · Reply
kev90123
kev90123 Apr. 29 at 8:21 PM
$HELP @HelusPharmaIR Doug said we needed the stock price to be above $5 so institutions would be able to buy. We need a reverse split asap otherwise they won't be able to buy anymore! Hurry!
0 · Reply
Buckwacker
Buckwacker Apr. 29 at 7:59 PM
$HELP Well shit…. I don’t even know what to say, think, damn it man….
0 · Reply
kev90123
kev90123 Apr. 29 at 5:59 PM
$HELP
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 29 at 5:58 PM
$HELP Current Stock Price: $4.97 Contracts to trade: $5.0 HELP May 15 2026 Call Entry: $0.40 Exit: $0.68 ROI: 69% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
kev90123
kev90123 Apr. 29 at 1:47 PM
$HELP All you needed to do is look at the founders of @HelusPharmaIR to realize this is a shell company. Paul Glavine didnt graduate from college and lives in the Bahamas and Eric So should arguably be in jail for crypto fraud.
1 · Reply
firetypecracker
firetypecracker Apr. 29 at 12:25 PM
$HELP H.C. Wainwright Keeps Their Buy Rating on Helus Pharma (HELP) In a report released today, from H.C. Wainwright, Patrick Trucchio reiterated a Buy rating on Helus Pharma, with a price target of $95.00.
0 · Reply
Horseman23
Horseman23 Apr. 29 at 11:24 AM
$HELP dark horse
0 · Reply
Buckwacker
Buckwacker Apr. 29 at 9:43 AM
$HELP https://finance.yahoo.com/sectors/healthcare/articles/helus-pharma-partners-tara-mind-113000608.html Come on and give this a boost, it’s really needed….
0 · Reply
leLu83
leLu83 Apr. 29 at 4:19 AM
$HELP using the ATM to dilute heavy in Q2 means they can hide it until August in the ER. These guys really know how to dilute like pros. All the accounting and SEC reporting tricks 💯 Too bad they put no effort into running a legit company bringing value to shareholders.
0 · Reply
leLu83
leLu83 Apr. 29 at 4:18 AM
$HELP heck yeah couldnt happen to a worse "company"
0 · Reply
firetypecracker
firetypecracker Apr. 28 at 9:54 PM
$HELP Capital Flow Analysis reveals inflows today into the stock from all three categories: large, medium, and small orders:
0 · Reply
grumpygoose
grumpygoose Apr. 28 at 9:23 PM
$HELP I'm tired boss
0 · Reply
firetypecracker
firetypecracker Apr. 28 at 7:59 PM
$HELP Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
0 · Reply
kev90123
kev90123 Apr. 28 at 6:05 PM
$HELP
0 · Reply
Waldo_5150
Waldo_5150 Apr. 28 at 5:57 PM
$HELP ...... As of early 2026, the company reports a robust IP estate consisting of more than 350 filed patent applications and over 100 granted patents globally. Status: Currently in Phase 3 clinical development .........
0 · Reply
prismmarketview
prismmarketview Apr. 28 at 5:27 PM
NASDA@: $HELP Helus Pharma is partnering with TARA Mind and VETS to support recruitment into its HLP003 Phase 3 PARADIGM trial and expand mental‑health outreach in veteran communities. Informational only, not investment advice. #HelusPharma #TARAMind #Veterans #MentalHealth #ClinicalTrials https://prismmarketview.com/helus-pharma-partners-with-tara-mind-to-boost-veteran-mental-health-outreach/
0 · Reply
Mastacash
Mastacash Apr. 28 at 3:01 PM
$HELP I like the partnership, aligns with the EO helping veterans, but Tara mind also deals with companies helping their employees, signals that we are gearing for commercialization.
0 · Reply